TABLE 3.

ICERs Per TB Case or Death Averted

	Strategy Alternatives	Incident TB Cases*	Incremental Cases Averted	Total Cost of Program	Incremental Cost of Program	ICER Per Case Averted
TST_H6	Provide only TST-positive PLHIV with 6-mo IPT, ART <250 cells/µL	318	—	$5,874,660	—	—
TST_H36	Provide only TST-positive PLHIV with 36-mo IPT, ART <250 cells/µL	198	120	$6,068,082	$193,422	$1612
TST_H6H36	Provide 6-mo IPT for TST-negatives, 36-mo IPT for TST-positives, ART <250 cells/µL	171	27	$6,244,913	$176,831	$6549
		Total Deaths†	Incremental Deaths Averted	Total Cost of Program	Incremental Cost of Program	ICER Per Death Averted
TST_H6	Provide only TST-positive PLHIV with 6-mo IPT, ART <250 cells/µL	301	—	$5,874,660	—	—
TST_H36	Provide only TST-positive PLHIV with 36-mo IPT, ART <250 cells/µL	221	80	$6,068,082	$193,422	$2,418
TST_H6H36	Provide 6-mo IPT for TST-negatives, 36-mo IPT for TST-positives, ART <250 cells/µL	218	3	$6,244,913	$176,831	$58,944
ART500	Discontinue IPT and increase ART initiation threshold to CD4 <500 cells/µL	171	47	$9,896,548	$3,651,635	$77,694

The current strategy ALL_H6 was dominated in the analysis and was not included in the final ICERs. ALL_H6 resulted in 321 total incident cases, 290 total deaths and $5,937,863 in total program costs.

^*Total number of new TB cases expected over the analytic horizon; excludes those diagnosed with TB at baseline.

^†Total number of deaths expected over the analytic horizon, including TB and all other causes.

^‡Extended dominance occurs when the ICER of an alternative is greater than the ICER of a more effective strategy, indicating an inefficient use of resources.

^§Absolute dominance occurs when an alternative is both less effective and more costly than other alternatives.